The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
May 23rd 2025
Explore 5 rare genetic and neurological disorders named after pioneering women in medicine, highlighting their significant contributions to previously unknown conditions.
Dr L. Elizabeth Budde: Mosunetuzumab Is Effective, Well Tolerated in R/R FL
December 11th 2021L. Elizabeth Budde, MD, PhD, oncologist and associate professor at City of Hope, discusses the use of mosunetuzumab in patients with relapsed/refractory follicular lymphoma (R/R FL) who have received 2 or more prior lines of therapy and addresses potential cost-related implications of the drug compared with CAR T-cell therapy.
Watch
Liso-Cel Offers “Breakthrough” in Second-Line Treatment of LBCL, Kamdar Says
December 11th 2021Results presented Saturday at the annual meeting of the American Society of Hematology show significant benefits in event-free survival, progression-free survival, and complete response over standard of care.
Read More
To Improve Outcomes, Identify Predictive Factors of PAH Earlier in Patients With SLE, Study Says
December 10th 2021Although pulmonary arterial hypertension (PAH) is a rare occurrence in systemic lupus erythematosus (SLE), a recent report details efforts by researchers to find an easy way to identify predictive factors, since having both diseases together reduces overall survival.
Read More
Liquid Biopsy Noninferior to Tissue-Based Genotyping in Management of Advanced NSCLC
December 10th 2021Cell-free circulating tumor DNA (cfDNA)–based tumor genotyping was found to be noninferior to standard-of-care tissue-based genotyping for detection of guideline-recommended biomarkers and therapeutic outcomes in patients with advanced nonsquamous non–small cell lung cancer (NSCLC).
Read More
Dr Andre Goy Previews Key Data on CAR T-Cell Therapy to Be Presented at ASH 2021
December 10th 2021Andre Goy, MD, MS, chairman and executive director of the John Theurer Cancer Center, provides an overview of the emerging data at ASH 2021 on CAR T-cell therapy as a second- and first-line treatment.
Watch
Study Examines Relapse Risk in GVHD After Allo-HCT Using 2 Therapy Options
December 9th 2021Despite the increase in relapse risk, 2-year survival for patients with graft-versus-host disease (GVHD) who received matched sibling donor (MSD) allogeneic hematopoietic cell transplant (allo-HCT) administered post-transplant cyclophosphamide remained similar compared with patients receiving cyclosporine A with methotrexate prophylactically.
Read More
Failed sedation for routine gastrointestinal (GI) endoscopy is extremely rare, warranting a return to endoscopist-directed sedation, rather than costly anesthesia-assisted sedation, as the default sedation standard.
Read More
Pediatric Patients With ASMD Show Significant Improvement in Olipudase Alfa Trial
December 4th 2021Findings from the single-arm, open-label ASCEND-Peds trial suggest olipudase alfa is well-tolerated and may lead to clinically meaningful improvements in patients with acid sphingomyelinase deficiency (ASMD) who do not have neurovisceral manifestations.
Read More
Genomic Profiling Identifies 3 NSCLC Subtypes Predictive of Adjuvant Therapy Outcomes
December 2nd 2021Next-generation sequencing uncovered 3 subtypes of epidermal growth factor receptor–mutant stage 2 and 3 non–small cell lung cancer (NSCLC) that predicted patient outcomes to adjuvant therapy.
Read More
Rituximab Infusion Timing, Dosing and COVID-19 Hospitalization Not Linked, Study Says
December 1st 2021A study examining the relation between rituximab infusion and hospitalization as a result of COVID-19 for patients with multiple sclerosis (MS) found that the 2 were not related, contradicting past research.
Read More
NGS, Prediction Tools Show Similarities Between Metastatic Breast Cancer, Other Advanced Cancers
November 27th 2021Next-generation sequencing (NGS) and the use of prediction tools in 2 patients with a rare form of metastatic breast cancer revealed mutations in malignant phyllodes tumors that are often detected in other advanced cancers, providing insight into potential therapeutic targets for these patients.
Read More